Company Overview
Tiziana Life Sciences Ltd operates within the healthcare sector, specifically focusing on the biotechnology industry where it develops transformative therapies for neurodegenerative and lung diseases in the United States. The company's strategic focus is anchored by its lead product candidate, Foralumab (TZLS-401), which is a human anti-CD3 monoclonal antibody designed for immunology applications. In terms of corporate scale, the company holds a market capitalization of $171.78M while employing a workforce of 9 individuals. The combination of a $171.78M market cap and the absence of reported annual revenue indicates that the company is in a pre-revenue or early-stage development phase, relying on capital markets and existing cash reserves rather than commercial sales to sustain operations. This valuation metric suggests the company is priced based on potential future clinical milestones and asset value rather than current earnings power, which is typical for biotechnology entities with significant research and development expenditures but no yet realized product revenue.
Financial Health
The company reported a net income of $-12,841,000 and an EBITDA of $-18,464,000 over the trailing twelve months, while revenue figures are not available due to the lack of commercial sales. The substantial negative net income relative to the zero revenue implies that the company's cost structure is dominated by high operating expenses, likely associated with research and development activities, clinical trial costs, and general administrative overheads that exceed any income generated. Free cash flow stands at $-3,856,625, indicating that the company is burning cash to fund its operations and development pipeline, which necessitates continuous access to external financing or existing liquidity reserves. All three reported margins—gross margin, operating margin, and profit margin—are listed at 0.0%, reflecting the current inability to generate commercial revenue and the resulting lack of profitability across all operational layers. The company holds $7.25M in cash against $107,000 in debt, resulting in a debt-to-equity ratio of 1.16, which suggests a balance sheet that is technically leveraged but with minimal absolute debt obligations relative to its cash position. A current ratio of 1.72 indicates that the company possesses sufficient current assets to cover its current liabilities, providing a moderate buffer for short-term liquidity needs despite the ongoing cash burn. Return on Equity is -232.3% and Return on Assets is -83.8%, metrics that reveal management is currently deploying capital in a manner that results in negative returns, a characteristic phase for biotechnology firms before product commercialization occurs.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -6.80, highlighting the discrepancy between historical performance and projected financials driven by anticipated future earnings recovery. The price-to-book ratio stands at 17.53, indicating that the market values the company at a significant premium of 17.53 times its tangible book value, a valuation multiple common in biotechnology where intangible assets and intellectual property are not fully reflected on the balance sheet. The price-to-sales ratio is N/A because there is no reported revenue, and the EV/EBITDA stands at -8.30, which suggests the valuation is being driven by enterprise value metrics rather than earnings multiples given the current loss position. The stock has traded between a 52-week low of $0.73 and a 52-week high of $2.60, placing the current trading range within a wide band that reflects high uncertainty and volatility typical of small-cap development-stage biotechs. The beta value is 0.26, indicating that the stock's price volatility is significantly lower than the broader market in recent periods, suggesting the stock may be priced in a way that decouples it from general market movements or that its specific risk profile is currently low due to limited liquidity or trading volume.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A due to the absence of commercial revenue and negative earnings, meaning no growth rate can be calculated to compare earnings expansion against revenue generation. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that earnings are not being distributed to shareholders but are instead retained to fund ongoing research and development efforts. Because the company is not a dividend payer, the entire financial profile is oriented toward capital appreciation through potential future product approvals and commercialization rather than current income generation. The overall growth and income profile is currently characterized by a lack of historical growth data and a complete absence of dividend income, relying entirely on the potential for future value creation from the development of therapies for neurodegenerative and lung diseases.